Antiviral compounds and methods

ABSTRACT

The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. application Ser. No. 14/071,870, filedNov. 5, 2013, which is a divisional of U.S. application Ser. No.11/922,281, filed Dec. 14, 2007, which is a U.S. national phase of PCTApplication No. PCT/AU2006/000880, filed Jun. 23, 2006, which claimspriority to Australian Application No. 2005903360, filed Jun. 24, 2005,the contents each of which is hereby incorporated by reference.

FIELD OF INVENTION

The present invention relates to novel compounds and compositions havingantiviral activity. The invention also relates to methods for retarding,reducing or otherwise inhibiting viral growth and/or functionalactivity.

BACKGROUND OF THE INVENTION

Currently, there is a great need for the development of new treatmentsthat are effective against viral infections, particularly against viralinfections which are associated with high morbidity and mortality, andwhich impact on sizable populations. Treatments currently available areinadequate or ineffective in large proportions of infected patients.

A large number of viruses contribute to the pool of significant humanpathogens. Examples of these include the viruses of the Lentivirus andFlavivirus families, for example HIV, Hepatitis C virus (HCV), Denguevirus and the like.

To improve the prospect of treating and preventing viral infections, andto deal with ongoing viral evolution, there is an on-going need toidentify molecules capable of inhibiting various aspects of the virallife cycle. A number of such compounds is disclosed inPCT/AU2004/000866. However, there is still a need for additional novelcompositions and agents with antiviral activity.

It is an object of the present invention to overcome or ameliorate atleast one of the disadvantages of the prior art, or to provide a usefulalternative.

Any discussion of the prior art throughout the specification should inno way be considered as an admission that such prior art is widely knownor forms part of common general knowledge in the field.

SUMMARY OF THE INVENTION

The inventors have surprisingly found that certain compounds that fallunder the classification of substituted acylguanidines have antiviralactivity against viruses from a range of different virus families. Anumber of such compounds is disclosed in PCT/AU2004/000866, incorporatedin its entirety herein by reference.

The present invention is concerned with certain novel antiviralcompounds that fall under the classification of substitutedacylguanidines.

According to a first aspect, the present invention provides compound of

wherein

R1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl or R1is selected from

and

n is 1, 2, 3 or 4;

F is independently

halogen, alkyl, halo or polyhalo alkyl;

Q is independently hydrogen, alkoxy especially methoxy, alkyl especiallymethyl, cycloalkyl, thienyl, furyl, pyrazolyl, substituted pyrazolyl,pyridyl, substituted pyridyl, phenyl, substituted phenyl, haloespecially chloro or bromo, heterocycle (“het”), or Q is independentlyselected from

wherein R2 is straight or branched chain alkyl,

where R3 is

and

X is hydrogen or alkoxy, and pharmaceutically acceptable salts thereof.

To the extent that any of the compounds were previously described inPCT/AU2004/000866 as anti-viral agents they are excluded from thepresent invention.

Preferably, the compounds of the invention include the following:

-   -(3-benzoyl)cinnamoylguanidine,-   5-methyl-2-napthoylguanidine,-   3(indan-4-yl)-propenoylguanidine,-   5-bromo-6-methoxy-2-napthoylguanidine,-   5-thiophen-3-yl-2-naphthoylguanidine,-   5-(1-methylpyrazol-4-yl)2-naphthoylguanidine,-   2,3-methylenedioxycinnamoyl guanidine,-   (1-methoxy-2-napthoyl)guanidine,-   (3-methoxy-2-napthoyl)guanidine,-   (5-bromo-2-napthoyl)guanidine,-   (1,4-dimethoxy-2-napthoyl)guanidine,-   (6-(3-thienyl)-2-napthoyl)guanidine,-   (6-methyl-2-napthoyl)guanidine,-   (5-phenyl-2-napthoyl)guanidine,-   (5-(thien-2-yl)-2-napthoyl)guanidine,-   (5-(1,3,5-trimethylpyrazol-4-yl)-2-napthoyl)guanidine,-   (5-(1-isobutyl-1H-pyrazol-4-yl)-2-napthoyl)guanidine,-   (5-(3-furyl)-2-napthoyl)guanidine,-   (5-cyclopropyl-2-napthoyl)guanidine,-   (5-chloro-2-napthoyl)guanidine,-   (6-(1-methylpryazol-4-yl)-2-napthoyl)guanidinium acetate,-   (5-(2,6-dimethoxypryridin-3-yl)-2-napthoyl)guanidine,-   (5-(2-chlorophenyl)-2-napthoyl)guanidine,-   (5-(4-(acetylamino)phenyl)-2-napthoyl)guanidine,-   (5-(3-(acetylamino)phenyl)-2-napthoyl)guanidine,-   (5-(4-((methylsulphonyl)amino)phenyl)-2-napthoyl)guanidine, and    pharmaceutically acceptable salts thereof.

The amine or imine groups of the guanidyl portion of the compounds ofFormula I can be present in any conventional form used for the provisionof such compounds. For example, they may be present as the free base, ahydrate, an organic or inorganic salt or combinations thereof.

Preferably, the compounds of the invention possess antiviral activityand are capable of reducing, retarding or otherwise inhibiting viralgrowth and/or replication. Examples of preferred viruses against whichthe compounds of the present invention are active, are viruses from theLentivirus and Flavivirus families. More preferably, the virus isHepatitis C virus (HCV), Human Immunodeficiency Virus (HIV) or Denguevirus. Most preferably, the virus is HCV, HIV-1 and HIV-2.

According to a second aspect, the present invention provides apharmaceutical composition comprising a compound according to the firstaspect, and optionally one or more pharmaceutical acceptable carriers orderivatives. The active compounds may be present in the form of anysuitable salt, adduct, in anhydrous or solvated forms.

In one embodiment, the compositions of the invention further compriseone or more known compounds or molecules having antiviral activity. Theknown antiviral compounds can be selected from the group consisting ofVidarabine, Acyclovir, Ganciclovir, Valganciclovir, Valacyclovir,Cidofovir, Famciclovir, Ribavirin, Amantadine, Rimantadine, Interferon,Oseltamivir, Palivizumab, Rimantadine, Zanamivir, nucleoside-analogreverse transcriptase inhibitors (NRTI) such as Zidovudine, Didanosine,Zalcitabine, Stavudine, Lamivudine and Abacavir, non-nucleoside reversetranscriptase inhibitors (NNRTI) such as Nevirapine, Delavirdine andEfavirenz, protease inhibitors such as Saquinavir, Ritonavir, Indinavir,Nelfinavir, Amprenavir, and other known antiviral compounds andpreparations.

According to a third aspect, there is provided a method for reducing,retarding or otherwise inhibiting growth and/or replication of a viruscomprising contacting a cell infected with said virus or exposed to saidvirus with a compound according to the first aspect.

According to a fourth aspect, there is provided a method for preventingthe infection of a cell exposed to a virus comprising contacting saidcell with a compound according to the first aspect.

According to a fifth aspect of the invention, there is provided a methodfor the therapeutic or prophylactic treatment of a subject exposed to orinfected with a virus comprising the administration to said subject of acompound according to the first aspect.

Preferably, the virus is from the Lentivirus and Flavivirus families.More preferably, the virus is Hepatitis C virus (HCV), HumanImmunodeficiency Virus (HIV) or Dengue virus. Most preferably, the virusis HCV, HIV-1 and HIV-2.

Preferably, the subject undergoing therapeutic or prophylactic treatmentis a mammal, such as, but not limited to, a human, primate, livestockanimal (e.g. sheep, cow, horse, donkey, pig), companion animal (e.g.dog, cat), laboratory test animal (e.g. mouse, rabbit, rat, guinea pig,hamster), or captive wild animal (e.g. fox, deer). Preferably, thesubject is a primate. Most preferably, the subject is a human.

Preferably, the pharmaceutical composition may further comprise one ormore known antiviral compounds or molecules. The known antiviralcompounds can be selected from the group consisting of Vidarabine,Acyclovir, Ganciclovir, Valganciclovir, Valacyclovir, Cidofovir,Famciclovir, Ribavirin, Amantadine, Rimantadine, Interferon,Oseltamivir, Palivizumab, Rimantadine, Zanamivir, nucleoside-analogreverse transcriptase inhibitors (NRTI) such as Zidovudine, Didanosine,Zalcitabine, Stavudine, Lamivudine and Abacavir, non-nucleoside reversetranscriptase inhibitors (NNRTI) such as Nevirapine, Delavirdine andEfavirenz, protease inhibitors such as Saquinavir, Ritonavir, Indinavir,Nelfinavir, Amprenavir, and other known antiviral compounds andpreparations.

In the event of any inconsistencies in the present specification betweenthe named compounds and the structural formula, the structural formulais to be preferred.

Unless the context clearly requires otherwise, throughout thedescription and the claims, the words ‘comprise’, ‘comprising’, and thelike are to be construed in an inclusive sense as opposed to anexclusive or exhaustive sense; that is to say, in the sense of“including, but not limited to”.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. BIT compound HIV-1_(Ba-L) inhibition and cell cytotoxicity inprimary human macrophages. The “% VC” dose response curves represent“percentage of control virus growth” figures calculated based on mean(of triplicate wells) virus levels in wells containing compound (atdecreasing conc.) compared to controls (no compound). HIV-1 levels weredetermined using p24 ELISA and converted to the percentage of controlvalues based on virus p24 levels detected in control culture wells thatdid not contain compound. The “% viability” curve was calculated fromOD560 nm data generated from MTT assays as a measure of cell viability.The OD values (mean of triplicate wells) were converted to a percentageof controls (containing no compound). The 50% level is indicated by thehorizontal line to allow for estimation of IC₅₀ and TC₅₀ values.

FIG. 2. Cell Cytotoxicity. The compounds were tested for cytotoxicity ata wide range of concentrations.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the surprising observationthat certain substituted acylguanidines have antiviral activity againsta broad range of viruses including those of the Lentivirus andFlavivirus families.

The present invention concerns compound of Formula I:

wherein

R1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl or R1is selected from

and

n is 1, 2, 3 or 4;

F is independently

halogen, alkyl, halo or polyhalo alkyl;

Q is independently hydrogen, alkoxy especially methoxy, alkyl especiallymethyl, cycloalkyl, thienyl, furyl, pyrazolyl, substituted pyrazolyl,pyridyl, substituted pyridyl, phenyl, substituted phenyl, haloespecially chloro or bromo, heterocycle (“het”), or Q is independentlyselected from

wherein R2 is straight or branched chain alkyl,

where R3 is

and

X is hydrogen or alkoxy, and pharmaceutically acceptable salts thereof.

To the extent that any of the compounds have been described previouslyin PCT/AU2004/000866 as anti-viral agents, they are excluded from thepresent invention. Particularly useful compounds may be selected fromthe following:

and pharmaceutically acceptable salts thereof. The amine or imine groupsof the guanidyl portion of the compounds of Formula I can be present inany conventional form used for the provision of such compounds. Forexample, they maybe present as the free base, a hydrate, an organic orinorganic salt or combinations thereof.

The methods developed for screening the compounds of the presentinvention for antiviral activity are described in detail inPCT/AU2004/000866, incorporated in its entirety herein by reference.

Reference to “HIV”, “HCV” and “Dengue virus” and the like should beunderstood as a reference to any HIV, HCV or Dengue virus strain andincluding homologues and mutants.

Reference to the “functional activity” of a virus should be understoodas a reference to any one or more of the functions which a virusperforms or is involved in.

Reference to the “viral replication” should be understood to include anyone or more stages or aspects of the viral life cycle, such asinhibiting the assembly or release of virions. Accordingly, the methodof the present invention encompasses the mediation of viral replicationvia the induction of a cascade of steps which lead to the mediation ofany one or more aspects or stages of the viral life cycle.

Reference to a “cell” infected with a virus should be understood as areference to any cell, prokaryotic or eukaryotic, which has beeninfected with a virus. This includes, for example, immortal or primarycell lines, bacterial cultures and cells in situ.

It will be understood by those skilled in the art that the compounds ofthe invention may be administered in the form of a composition orformulation comprising pharmaceutically acceptable carriers and/orexcipients.

The pharmaceutical compositions of the invention may further compriseone or more known antiviral compounds or molecules. Preferably, theknown antiviral compounds are selected from the group consisting ofVidarabine, Acyclovir, Ganciclovir, Valganciclovir, Valacyclovir,Cidofovir, Famciclovir, Ribavirin, Amantadine, Rimantadine, Interferon,Oseltamivir, Palivizumab, Rimantadine, Zanamivir, nucleoside-analogreverse transcriptase inhibitors (NRTI) such as Zidovudine, Didanosine,Zalcitabine, Stavudine, Lamivudine and Abacavir, non-nucleoside reversetranscriptase inhibitors (NNRTI) such as Nevirapine, Delavirdine andEfavirenz, protease inhibitors such as Saquinavir, Ritonavir, Indinavir,Nelfinavir, Amprenavir, and other known antiviral compounds andpreparations.

The subject of the viral inhibition is a mammal, such as, but notlimited to a human, primate, livestock animal (e.g. sheep, cow, horse,donkey, pig), companion animal (e.g. dog, cat), laboratory test animal(e.g. mouse, rabbit, rat, guinea pig, hamster), or captive wild animal(e.g. fox, deer). Preferably, the subject is a human. Most preferably,the subject is a human.

The method of the present invention is useful in the treatment andprophylaxis of viral infection such as, for example, HIV, HCV, Dengueand other viral infections. For example, the antiviral activity may beaffected in subjects known to be infected with HIV in order to preventreplication of HIV thereby preventing the onset of AIDS. Alternatively,the method of the present invention may be used to reduce serum viralload or to alleviate viral infection symptoms. This concept applies toany viral infection.

The method of the present invention may be particularly useful either inthe early stages of viral infection to prevent the establishment of aviral reservoir in affected cells or as a prophylactic treatment to beapplied immediately prior to or for a period after exposure to apossible source of virus.

Reference herein to “therapeutic” and “prophylactic” is to be consideredin their broadest contexts. The term “therapeutic” does not necessarilyimply that a mammal is treated until total recovery. Similarly,“prophylactic” does not necessarily mean that the subject will noteventually contract a disease condition. Accordingly, therapy andprophylaxis include amelioration of the symptoms of a particularcondition or preventing or otherwise reducing the risk of developing aparticular condition. The term “prophylaxis” may be considered asreducing the severity of onset of a particular condition. Therapy mayalso reduce the severity of an existing condition or the frequency ofacute attacks.

In accordance with the methods of the present invention, more than onecompound or composition may be co-administered with one or more othercompounds, such as known anti-viral compounds or molecules. By“co-administered” is meant simultaneous administration in the sameformulation or in two different formulations via the same or differentroutes or sequential administration by the same or different routes. By“sequential” administration is meant a time difference of from seconds,minutes, hours or days between the administration of the two or moreseparate compounds. The subject antiviral compounds may be administeredin any order.

Routes of administration include, but are not limited to, intravenous,intraperitoneal, subcutaneous, intracranial, intradermal, intramuscular,intraocular, intrathecal, intracerebral, intranasal, transmucosal, or byinfusion orally, rectally, via iv drip, patch and implant. Intravenousroutes are particularly preferred.

Compositions suitable for injectable use include sterile aqueoussolutions (where water soluble) and sterile powders for theextemporaneous preparation of sterile injectable solutions. The carriercan be a solvent or dispersion medium containing, for example, water,ethanol, polyol (for example, glycerol, propylene glycol and liquidpolyethylene glycol, and the like), suitable mixtures thereof andvegetable oils. The prevention of the action of microorganisms can bebrought about by various antibacterial and antifungal agents, forexample, parabens, chlorobutanol, phenol, sorbic acid, thimerosal andthe like. In many cases, it will be preferable to include isotonicagents, for example, sugars or sodium chloride. Prolonged absorption ofthe injectable compositions can be brought about by the use in thecompositions of agents delaying absorption, for example, aluminummonostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the activecompounds in the required amount in the appropriate solvent with variousof the other ingredients enumerated above, as required, followed by, forexample, filter sterilization or sterilization by other appropriatemeans. Dispersions are also contemplated and these may be prepared byincorporating the various sterilized active ingredients into a sterilevehicle which contains the basic dispersion medium and the requiredother ingredients from those enumerated above. In the case of sterilepowders for the preparation of sterile injectable solutions, a preferredmethod of preparation includes vacuum drying and the freeze-dryingtechnique which yield a powder of the active ingredient plus anyadditional desired ingredient from a previously sterile-filteredsolution.

When the active ingredients are suitably protected, they may be orallyadministered, for example, with an inert diluent or with an assimilableedible carrier, or it may be enclosed in hard or soft shell gelatincapsule, or it may be compressed into tablets. For oral therapeuticadministration, the active compound may be incorporated with excipientsand used in the form of ingestible tablets, buccal tablets, troches,capsules, elixirs, suspensions, syrups, wafers, and the like. Suchcompositions and preparations should contain at least 0.01% by weight,more preferably 0.1% by weight, even more preferably 1% by weight ofactive compound. The percentage of the compositions and preparationsmay, of course, be varied and may conveniently be between about 1 toabout 99%, more preferably about 2 to about 90%, even more preferablyabout 5 to about 80% of the weight of the unit. The amount of activecompound in such therapeutically useful compositions is such that asuitable dosage will be obtained. Preferred compositions or preparationsaccording to the present invention are prepared so that an oral dosageunit form contains between about 0.1 ng and 2000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain thecomponents as listed hereafter: A binder such as gum, acacia, cornstarch or gelatin; excipients such as dicalcium phosphate; adisintegrating agent such as corn starch, potato starch, alginic acidand the like; a lubricant such as magnesium stearate; and a sweeteningagent such as sucrose, lactose or saccharin may be added or a flavouringagent such as peppermint, oil of wintergreen, or cherry flavouring. Whenthe dosage unit form is a capsule, it may contain, in addition tomaterials of the above type, a liquid carrier. Various other materialsmay be present as coatings or to otherwise modify the physical form ofthe dosage unit. For instance, tablets, pills, or capsules may be coatedwith shellac, sugar or both. A syrup or elixir may contain the activecompound, sucrose as a sweetening agent, methyl and propylparabens aspreservatives, a dye and flavouring such as cherry or orange flavour.Any material used in preparing any dosage unit form should bepharmaceutically pure and substantially non-toxic in the amountsemployed. In addition, the active compound(s) may be incorporated intosustained-release preparations and formulations.

The present invention also extends to forms suitable for topicalapplication such as creams, lotions and gels. In such forms, theanti-clotting peptides may need to be modified to permit penetration ofthe surface barrier.

Procedures for the preparation of dosage unit forms and topicalpreparations are readily available to those skilled in the art fromtexts such as Pharmaceutical Handbook. A Martindale Companion Volume Ed.Ainley Wade Nineteenth Edition The Pharmaceutical Press London, CRCHandbook of Chemistry and Physics Ed. Robert C. Weast Ph D. CRC PressInc.; Goodman and Gilman's; The Pharmacological basis of Therapeutics.Ninth Ed. McGraw Hill; Remington; and The Science and Practice ofPharmacy. Nineteenth Ed. Ed. Alfonso R. Gennaro Mack Publishing Co.Easton Pa.

Pharmaceutically acceptable carriers and/or diluents include any and allsolvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents and the like. The use ofsuch media and agents for pharmaceutically active substances is wellknown in the art. Except insofar as any conventional media or agent isincompatible with the active ingredient, use thereof in the therapeuticcompositions is contemplated. Supplementary active ingredients can alsobe incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions indosage unit form for ease of administration and uniformity of dosage.Dosage unit form as used herein refers to physically discrete unitssuited as unitary dosages for the mammalian subjects to be treated; eachunit containing a predetermined quantity of active material calculatedto produce the desired therapeutic effect in association with therequired pharmaceutical carrier. The specification for the novel dosageunit forms of the invention are dictated by and directly dependent on(a) the unique characteristics of the active material and the particulartherapeutic effect to be achieved and (b) the limitations inherent inthe art of compounding.

Effective amounts contemplated by the present invention will varydepending on the severity of the condition and the health and age of therecipient. In general terms, effective amounts may vary from 0.01 ng/kgbody weight to about 100 mg/kg body weight.

Alternative amounts include for about 0.1 ng/kg body weight about 100mg/kg body weight or from 1.0 ng/kg body weight to about 80 mg/kg bodyweight.

The subject of the viral inhibition is generally a mammal such as butnot limited to human, primate, livestock animal (e.g. sheep, cow, horse,donkey, pig), companion animal (e.g. dog, cat), laboratory test animal(e.g. mouse, rabbit, rat, guinea pig, hamster), captive wild animal(e.g. fox, deer). Preferably, the subject is a human or primate. Mostpreferably, the subject is a human.

The present invention will now be described in more detail withreference to specific but non-limiting examples describing syntheticprotocols, viral inhibition and other anti-viral properties of thecompounds of the present invention. Synthesis and screening forcompounds that have antiviral activity can be achieved by the range ofmethodologies described herein or described in more detail inPCT/AU2004/000866, incorporated in its entirety herein by reference.

It is to be understood, however, that the detailed description ofspecific procedures, compounds and methods is included solely for thepurpose of exemplifying the present invention. It should not beunderstood in any way as a restriction on the broad description of theinvention as set out above.

EXAMPLES

Anti-viral activity of all the compounds of the present invention canbe, and has been, ascertained using the methods described herein ordescribed in detail in PCT/AU2004/000866, incorporated in its entiretyherein by reference. Further, methods for synthesis of the compounds ofthe invention, both generic and specific, described herein, described inreferenced publications or otherwise known to those skilled in the art,can be used to prepare all the compounds of the present invention.

More specifically, acylguanidines can be synthesised by a variety ofmethods including reacting guanidine (generally generated in situ fromits hydrochloride salt) with a suitably activated derivative of acarboxylic acid. Examples include:

-   i) synthesis from acid chlorides, exemplified by Yamamoto et al.,    Chem. Pharm. Bull., 1997, 45, 1282-   ii) synthesis from simple esters, exemplified by U.S. Pat. No.    2,734,904.-   iii) synthesis from carboxylic acids, via in situ activation by    carbonyldiimidazole, exemplified by U.S. Pat. No. 5,883,133

The carboxylic acid precursors required for the preparation of theacylguanidines described herein were obtained by a variety of diversemethods. A large number of the substituted cinnamic acids arecommercially available. In addition, numerous procedures for thesynthesis of substituted cinnamic acids and their simple esters are welldescribed in the art, including:

-   i) The reaction of malonic acid with an aromatic aldehyde and base    (the Doebner Condensation), described in Chemical Reviews, 1944, 35,    156, and references contained therein.-   ii) The reaction of acetic anhydride with an aromatic aldehyde and    base (the Perkin Reaction), described in Organic Reactions, 1942, 1,    210, and references contained therein.-   iii) The reaction of acrylic acid and simple esters thereof with an    aromatic halide or aromatic triflate using palladium catalyst (the    Heck Reaction), described in Organic Reactions, 1982, 28, 345, and    references contained therein.-   iv) The reaction of a trialkyl phosphonoacetate with an aromatic    aldehyde and base (the Horner-Emmons Reaction), described in Organic    Reactions, 1977, 25, 73, and references contained therein.

A number of simple halo, hydroxy, and alkoxy substituted naphthoic acidsare either commercially available or known in the art and these providedthe starting materials for the susbstituted naphthoylguanidines.

Naphthoic acids which are substituted with alkyl, cycloalkyl, aryl, andheterocyclic groups can often be prepared by reacting a halonaphthoicacid with a suitable organometallic reagent using a transition metalcatalyst. One such variant of this methodology which was used to preparea number of the substituted naphthoic acids used as precursors to thenaphthoylguanidines described herein, was the palladium-catalyzedcarbon-carbon bond forming reaction between bromonaphthoic acids and asuitably substituted boronic acid (or boronate ester) which is widelyknown in the art as the Suzuki coupling (described in Chemical Reviews,1995, 95, 2457 and references therein). The reaction has wideapplicability and can be used on a range of substituted halonaphthaleneswhich can then be further elaborated to introduce or unmask the requiredcarboxylic acid group.

1. GENERAL SYNTHETIC METHODOLOGY 1.1 General Procedure A—Preparation ofAryl Triflates

To a solution of the phenol (10 mmol) in pyridine (7 mL) at 0° C. wasslowly added trifluoromethanesulphonic anhydride (11 mmol, 1.1 eq). Theresulting mixture was stirred at 0° C. for a further 5 minutes beforebeing allowed to warm to room temperature and stirred until TLC analysisshowed that the starting phenol had been consumed. The mixture was thenpoured into water and extracted with ethyl acetate (×3). The combinedextracts were washed sequentially with water, 1M aqueous hydrochloricacid, water and brine, then dried (MgSO₄) and concentrated in vacuo togive the crude product. The crude products were chromatographed oversilica gel. Elution with a mixture of ethyl acetate/hexanes gave thedesired aryl triflates, generally as colourless oils.

1.2 General Procedure B—Cinnamate Esters Via Heck Reaction of Triflates

A mixture of the phenyl triflate (10 mmol), methyl acrylate (14 mmol,1.4 eq), triethylamine (40 mmol, 4 eq) anddichlorobis(triphenylphosphine)palladium (0.3 mmol, 0.03 eq) indimethylformamide (30 mL) was heated at 90° C. The reaction wasmonitored by GC/MS and fresh batches of methyl acrylate (1 eq),triethylamine (2 eq) and the palladium catalyst (0.03 eq) were added asrequired, in an effort to force the reaction to completion. The mixturewas then poured into water and extracted with a 1:1 mixture of diethylether/hexanes (×3). The combined extracts were washed with water, thenbrine, dried (MgSO₄), filtered through a pad of silica gel and thefiltrate was concentrated in vacuo to give the crude product as an oil.The crude products were chromatographed over silica gel. Elution with amixture of ethyl acetate/hexanes gave the desired methyl cinnamates,generally as colourless oils.

1.3 General Procedure C—Cinnamate Esters Via Heck Reaction of Bromides

The aryl bromide (10 mmol), palladium acetate (0.1 mmol, 0.01 eq) andtri-o-tolylphosphine (0.4 mmol, 0.04 eq) was added to the reaction flaskand purged with nitrogen. To this, methyl acrylate (12.5 mmol, 1.25 eq),triethylamine (12.5 mmol, 1.25 eq) and dimethylformamide (1 mL) werethen added and the mixture was heated at 100° C. The reaction wasmonitored by GC/MS and fresh batches of palladium acetate (0.01 eq),tri-o-tolylphosphine (0.04 eq), methyl acrylate (1.25 eq) andtriethylamine (1.25 eq) were added as required, in an effort to forcethe reaction to completion. The mixture was poured into water andextracted with a 1:1 mixture of diethyl ether/hexanes (×4). The combinedextracts were washed with water, then brine, dried (MgSO₄), filteredthrough a pad of silica gel and the filtrate was concentrated in vacuoto give the crude product. The crude products were chromatographed oversilica gel. Elution with a mixture of ethyl acetate/hexanes gave thedesired methyl cinnamates, generally as colourless oils.

1.4 General Procedure D—Cinnamate Esters Via Horner-Emmons Reaction

A solution of triethyl phosphonoacetate (13 mmol, 1.3 eq) in anhydroustetrahydrofuran (10 mL) was added, over 5 minutes, to a suspension ofsodium hydride (14.3 mmol, 1.4 eq) in anhydrous tetrahydrofuran (10 mL)at 0° C. under nitrogen. The mixture was then stirred at 0° C. for 20minutes. A solution of the benzaldehyde (10 mmol) in tetrahydrofuran (15mL) was then added over 10 minutes at 0° C. The mixture was stirred at0° C. for a further 30 minutes before being allowed to stir at roomtemperature until GC/MS or TLC analysis showed that the benzaldehydestarting material had been consumed. Typically, reactions were allowedto stir at room temperature overnight to ensure complete consumption ofthe starting aldehyde. The mixture was poured into water, the organiclayer was separated and the aqueous layer was extracted with ethylacetate (×3). The combined organic extracts were then washed with water,then brine, dried (MgSO4) and concentrated in vacuo to give the crudeproduct. The crude products were chromatographed over silica gel.Elution with a mixture of ethyl acetate/hexanes gave the desired ethylcinnamates, generally as colourless oils.

1.5 General Procedure E—Preparation of 5-Phenylpenta-2,4-Dienoic Esters

A solution of triethyl 4-phosphonocrotonate (26 mmol, 1.3 eq) inanhydrous tetrahydrofuran (10 mL) was added, over 5 minutes, to asuspension of sodium hydride (28 mmol, 1.4 eq, 60% suspension in oil) inanhydrous tetrahydrofuran (15 mL) at 0° C. under nitrogen. The mixturewas then stirred at 0° C. for 20 minutes. A solution of the benzaldehyde(20 mmol) in tetrahydrofuran (10 mL) was then added over 10 minutes at0° C. The mixture was stirred at 0° C. for a further 30 minutes and thenit was allowed to stir at room temperature until GC/MS analysis showedthat the starting aldehyde had been consumed. The reaction mixture waspoured into water, the organic layer was separated and the aqueous layerwas extracted with ethyl acetate (×3). The combined organic extractswere then washed with water, then brine, dried (MgSO₄) and concentratedin vacuo to give the crude ethyl ester as an oil. The crude productswere chromatographed over silica gel. Elution with a mixture of ethylacetate/hexanes gave the desired ethyl esters as colourless oils.

1.6 General Procedure F—Hydrolysis of Esters

A solution of the ester (10 mmol) in methanol (50 mL) and water (5 mL)was treated with an aqueous solution of 6M potassium hydroxide (20 mmol,2 eq) and the mixture was heated under reflux until TLC analysis showedthat no more starting material was present (usually 2-3 hours). Themixture was then poured into water (50-200 mL) and acidified withconcentrated hydrochloric acid to approximately pH 2. The resultingcarboxylic acid was collected by filtration, washed with water and driedovernight under high vacuum.

1.7 General Procedure G—Suzuki Reactions of Bromonaphthoic Acids

The bromo-2-naphthoic acid (2 mmol), the appropriate boronic acid (orboronate ester) (2.2 mmol), tetrakis(triphenylphosphine)palladium(0)(0.1 mmol), and solid sodium carbonate (6.8 mmol) were added to thereaction flask which was then purged with nitrogen. Acetonitrile (6 mL)and water (2.5 mL) were added and the mixture was heated under refluxwith vigorous stirring until the starting bromo-2-naphthoic acid hadbeen consumed. The reaction mixture was then partitioned between toluene(50 mL) and 0.5M sodium hydroxide solution (100 mL). The aqueous layerwas washed with toluene (to remove any triphenylphosphine, 3×20 mL) thenacidified to pH 1 with concentrated hydrochloric acid. The naphthoicacid derivatives were extracted into ethyl acetate (4×20 mL). Thecombined ethyl acetate extracts were washed with water (3×20 mL) andbrine (10 mL), then dried (MgSO₄), filtered, and concentrated. Theresidue was analyzed by ¹H NMR, and chromatographed over silica gel (ifrequired).

1.8 General Procedure H—Preparation of Acylguanidines

To a suspension/solution of carboxylic acid (10 mmol, 1.0 eq) indichloromethane (30 mL) containing a drop of dimethylformamide was addedoxalyl chloride (12 mmol, 1.2 eq) which caused the solution toeffervesce. After stirring for 2 h, the resulting solution wasevaporated to dryness under reduced pressure. The residue was dissolvedin dry tetrahydrofuran (30 mL) and added to a solution of guanidinehydrochloride (50 mmol, 5.0 eq) in 2M aqueous sodium hydroxide (30 mL).The reaction was stirred at room temperature for 1 h and then thetetrahydrofuran layer was separated. The aqueous layer was extractedwith chloroform (100 mL) followed by ethyl acetate (100 mL) and thecombined organic layers evaporated under reduced pressure. The resultingresidue was partitioned between chloroform (200 mL) and 2M aqueoussodium hydroxide (100 mL) and the organic layer was separated and dried(Na₂SO₄). The solution was filtered and evaporated under reducedpressure to the point where a solid began to precipitate. At this pointhexanes were added causing precipitation of the product which wascollected by filtration and dried under high vacuum.

2. SPECIFIC EXPERIMENTAL EXAMPLES OF SYNTHESES Example 1 4-Hydroxyindan

4-Aminoindan (3.0 g) was added to a solution of concentrated sulphuricacid (2.4 mL) in water (15 mL). More water (15 mL) was added and themixture cooled to 5° C. A solution of sodium nitrite (1.71 g) in water(4.5 mL) was added portionwise to the mixture while maintaining thetemperature below 5° C. After addition was complete the mixture wasallowed to warm to room temperature and urea (0.29 g) was added. Themixture was stirred for a further 5 minutes before being heated at 45°C. for 30 minutes. The mixture was then cooled to room temperature andextracted with ethyl acetate. The combined organic extracts were washedwith 2M aqueous sodium hydroxide (2×100 mL) and these aqueous extractswere then acidified with hydrochloric acid and extracted with ethylacetate (3×100 mL). The combined organic extracts were then washed withbrine and dried (Na₂SO₄) before being concentrated in vacuo. Theresulting crude product was chromatographed over silica gel. Elutionwith ethyl acetate/hexanes (1:7) gave 4-hydroxyindan as an orange oil(1.0 g).

Example 2 4-Indanyl Triflate

To a solution of 4-hydroxyindan (1.2 g, 8.9 mmol) in pyridine (5 mL) at0° C. was slowly added trifluoromethanesulphonic anhydride (1.6 mL, 9.8mmol). The resulting mixture was stirred at 0° C. for 5 minutes beforebeing allowed to warm to room temperature and then stirred for 45minutes. The mixture was then poured into water and extracted with ethylacetate (3×25 mL). The combined extracts were washed sequentially withwater, 1M aqueous hydrochloric acid, water and brine, then dried(Na₂SO₄) and concentrated in vacuo to give the crude triflate as anorange oil (2.13 g, 89%).

Example 3 Methyl 3-(indan-4-yl)acrylate

A mixture of crude 4-indanyl triflate (2.13 g, 8.0 mmol), methylacrylate (1.01 mL, 11.2 mmol), triethylamine (4.4 mL, 32 mmol, 4 eq) anddichlorobis(triphenylphosphine)palladium (170 mg 0.24 mmol) indimethylformamide (15 mL) was heated at 85° C. for 71 hours. A smallaliquot was removed and worked up for GC/MS analysis which revealed asignificant amount of starting material was still present. Additionalmethyl acrylate (0.7 mL), triethylamine (2 mL) and the palladiumcatalyst (170 mg) were added and the mixture was heated for a further 24hours. The mixture was then poured into water, extracted with ethylacetate, and the organic extracts were washed with water, then brine,dried (Na₂SO₄), and concentrated in vacuo to give the crude product asan oil (2.4 g). The crude product was chromatographed over silica gel.Elution with ethyl acetate/hexanes (1:19) gave the starting triflate(812 mg, 38%) as a colourless oil, followed by the desired methyl3-(indan-4-yl)acrylate as a brown oil (880 mg, 54%).

Example 4 Methyl 3-benzoylcinnamate

To a mixture of 3-bromobenzophenone (5.0 g, 19 mmol), palladium acetate(215 mg, 0.958 mmol), and tri-o-tolylphosphine (290 mg, 0.953 mmol) wasadded triethylamine (3.3 mL, 45 mmol), toluene (4 mL), and methylacrylate (2.2 mL, 27 mmol). The mixture was heated at 100° C. for 18hours at which time −TLC analysis showed the reaction was stillincomplete. Additional portions of palladium acetate (215 mg, 0.958mmol), tri-o-tolylphosphine (290 mg, 0.953 mmol), triethylamine (3.3 mL,45 mmol) and methyl acrylate (2.2 mL, 27 mmol) were added, and themixture was heated at 110° for a further 18 hours. After cooling to roomtemperature the mixture was poured into water and extracted with ethylacetate (3×100 mL). The combined organic extracts were washedsequentially with water and brine, and then dried (MgSO₄) andconcentrated to a brown oil (5.3 g). The oil was chromatographed oversilica gel. Elution with ethyl acetate/hexanes (1:9) afforded methyl3-benzoylcinnamate (4.6 g, 91%) as a yellow solid.

Example 5 3-Benzoylcinnamic Acid

Aqueous 5M potassium hydroxide (10 mL, 50 mmol) was added to a solutionof methyl 3-benzoylcinnamate (2.5 g, 9.4 mmol) in methanol (20 mL) andthe mixture was stirred at room temperature for 18 hours. The mixturewas concentrated and acidified to pH 1 using 1M aqueous hydrochloricacid. The resulting precipitate was collected by filtration and driedunder vacuum to give 3-benzoylcinnamic acid (2.2 g, 93%) as a yellowsolid.

Example 6 5-(1-Methyl-1H-pyrazol-4-yl)-2-naphthoic acid

A mixture of 5-bromo-2-naphthoic acid (2.12 g, 8.44 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1.84 g, 8.86 mmol), and tetrakis(triphenylphosphine)palladium(0) (502mg, 0.435 mmol) in a 250 mL round bottomed flask was evacuated andpurged with nitrogen (in three cycles). Acetonitrile (40 mL) and 2Maqueous sodium carbonate (10 mL) were added to the mixture via syringe,and the mixture was heated under reflux under nitrogen for 22 hours. Thereaction mixture was allowed to cool before the addition of 1M aqueoushydrochloric acid (30 mL) and it was then extracted with ethyl acetate(3×50 mL). The combined organic layers were dried (MgSO₄), filtered, andconcentrated in vacuo to provide a crude product (2.98 g after airdrying). This crude material was dissolved in hot ethanol (150 mL) andfiltered while hot to remove a yellow impurity (120 mg). The filtratewas concentrated in vacuo and the residue was recrystallised fromdichloromethane (30 mL) to provide5-(1-methyl-1H-pyrazol-4-yl)-2-naphthoic acid as a white solid (724 mg,34%). A second crop of 5-(1-methyl-1H-pyrazol-4-yl)-2-naphthoic acid(527 mg, 25%) was obtained from the concentrated mother liquors byrecrystallisation from dichloromethane (20 mL).

Example 7 5-(1-Methyl-1H-pyrazol-4-yl)-2-naphthoylguanidine

Oxalyl chloride (1.1 mL, 13 mmol) was added to a solution of5-(1-methyl-1H-pyrazol-4-yl)-2-naphthoic acid (1.19 g, 4.71 mmol) inanhydrous dichloromethane (200 mL (which was added in portions duringthe reaction to effect dissolution)) containing dimethylformamide (2drops) under nitrogen and the mixture was stirred at room temperaturefor 4.25 hours. The reaction mixture was then heated for 1 hour at 40°C., before being concentrated under reduced pressure. The resultingcrude acid chloride was suspended in anhydrous tetrahydrofuran (50 mL)and this mixture was added dropwise to a solution of guanidinehydrochloride (2.09 g, 21.9 mmol) in 2M aqueous sodium hydroxide (15 mL,30 mmol) and the reaction mixture was then stirred for 30 minutes. Theorganic phase was separated, and the aqueous phase was extracted withchloroform (3×30 mL) followed by ethyl acetate (3×30 mL). The combinedorganic extracts were washed sequentially with 1M aqueous sodiumhydroxide (60 mL) and water (40 mL), then dried (Na₂SO₄) andconcentrated in vacuo to give a glassy solid (1.45 g after drying underhigh vacuum). This solid was dissolved in dichloromethane which was thenallowed to evaporate slowly to give5-(1-methyl-1H-pyrazol-4-yl)-2-naphthoylguanidine as a yellow solid(1.15 g, 83%).

Example 8 Ethyl 2,3-methylenedioxycinnamate

Triethyl phosphonoacetate (4.05 mL, 20.2 mmol) was added dropwise to astirred suspension of sodium hydride (0.80 g, 20 mmol) in anhydroustetrahydrofuran (20 mL) at 0° C. under nitrogen. The mixture was stirredat 0° C. for 20 minutes. A solution of 2,3-methylenedioxybenzaldehyde(2.50 g, 16.7 mmol) in tetrahydrofuran (10 mL) was added dropwise at 0°C. The mixture was stirred for 2 hours during which time it was allowedto warm to room temperature. The mixture was poured into water (250 mL),and extracted with ethyl acetate (3×250 mL). The combined organicextracts were then washed with brine, dried (MgSO₄) and concentrated invacuo. The crude product was chromatographed over silica gel. Elutionwith ethyl acetate/hexanes (1:10) gave ethyl 2,3-methylenedioxycinnamateas a colourless solid (3.50 g, 92%).

Example 9 2,3-Methylenedioxycinnamic Acid

A solution of ethyl 2,3-methylenedioxycinnamate (3.40 g) in methanol (25mL) and water (5 mL) was treated with a solution of potassium hydroxide(4.3 g) in water (25 mL). The mixture was stirred overnight at roomtemperature before being concentrated in vacuo to half its originalvolume. The concentrate was then acidified with concentrated HCl to give2,3-methylenedioxycinnamic acid as a colourless solid (2.81 g, 95%)which was collected by filtration and dried overnight under a vacuum.

Example 10 2,3-Methylenedioxycinnamoylguanidine

Oxalyl chloride (0.68 mL, 7.8 mmol) was added to a suspension of2,3-methylenedioxycinnamic acid (500 mg, 2.6 mmol) in dichloromethane (5mL) containing a drop of dimethylformamide. The mixture was stirred for2.5 hours and the resulting solution was evaporated to dryness underreduced pressure. The residue was dissolved in dry tetrahydrofuran (5mL) and added to a solution of guanidine hydrochloride (1.24 g, 13 mmol)in 2M aqueous sodium hydroxide (8 mL). The reaction was stirred at roomtemperature for 1 hour and chloroform was then added. The resultingprecipitate of crude product (100 mg) was collected by filtration. Thefiltrate was extracted with chloroform (3×30 mL) and ethyl acetate (20mL). The combined organic extracts were washed with 2M aqueous sodiumhydroxide (20 mL), water (20 mL), dried (Na₂SO₄) and concentrated underreduced pressure to give a further quantity of crude product (400 mg).The two crops of crude product were combined, suspended in chloroform(10 mL) and stirred vigorously for 20 minutes. The resulting2,3-methylenedioxycinnamoylguanidine (420 mg) was collected byfiltration and dried under vacuum.

Example 11 Viral Inhibition Assays

As indicated earlier, methods used to screen for anti-viral activity ofthe compounds of the present invention have been described in detail inPCT/AU2004/000866, incorporated in its entirety herein by reference.

The inhibition specifically of HIV-1 growth by the compounds of theinvention was tested in primary macrophages in vitro using a methodsimilar to that used to assess antibody neutralization (VanCott T C etal (1999)). In the present case, the laboratory adapted HIV-1 strainBa-L was used, which is known to infect macrophages.

11.1 Macrophage Preparation

Peripheral Blood Mononuclear Cells (PBMC) were prepared from healthydonors using buffy-coat packs obtained from the Australian Red CrossBlood Service (ARCBS). Blood was received the day following donation,and had been depleted of serum and platelets, leaving a small volume(less than 100 mL) of concentrated leukocytes.

Leukocytes were separated from blood cells and granulocytes by densitygradient centrifugation (Ficoll Paque) and washed extensively in PBS⁻(without Ca/Mg) to remove platelets. Recovered cells were allowed toadhere to plastic tissue culture flasks (Becton Dickinson) for 2 hr, 37°C., 5% CO₂, in media (DMEM (high)/10% AB serum/50 ug/mL gentamicin/2 mML-glutamine) during which time the myeloid cells formed an adherentmonolayer leaving lymphocytes unattached.

Non-adherent lymphocytes were removed by washing with warm PBS⁺ (withCa/Mg) and were generally discarded. In some cases those cells wererecovered and frozen in media/10% DMSO for use in viral stockinfections. The adherent monocytes were recovered by scraping gentlywith a plastic cell scraper. The myeloid cells were then plated into96-well plates at a cell concentration of 1.5×10⁶/mL, and allowed tofully differentiate over a period of 14 days.

11.2 Assay Protocol

Macrophages were allowed to differentiate over a 14 day period, withmedia changes as required. On day 14, cells were infected in thepresence of decreasing concentrations of BIT compounds over a range 0-10μM. Samples of 25 μL culture supernatants were removed from each well onday 7 and fresh media plus compound dilution was added.

11.3 Analysis of Viral Inhibition

After 7 days the samples with and without compound were analysed toassess the level of virus present in the wells, using a p24 ELISA(Innotest). Virus levels in samples were converted to “percentage ofcontrol virus growth” values based on the controls (containing nocompound). From that dose response curve (example FIG. 1) the IC₅₀ wascalculated and used as a measure of compound anti-HIV activity.

11.4 Cytotoxicity

The toxicity of test compounds to cells in the viral inhibition assaywas determined using the MTT assay (Pauwels R, et al. (1988); D'Cruz O Jet al. (1999); Joo H. (2003)). This method utilises Thiazolyl Blue(MTT), which is added to the cell culture (100 ug/well), and incubatedfor 4-5 hours whilst the live, metabolically active cells convert thechemical to its purple coloured metabolite, which forms intracellularcrystals. The purple colour is measured colourimetrically (570-590 nm)once cells have been permeabilised using acidified isopropanolcontaining 10% triton X-100. The most intense colour development occursin wells where the metabolising cells are most numerous.

The measured OD values were converted to “percentage viability” figuresbased on the controls (containing no compounds) and the value at which50% cell viability (TC₅₀) was measured could then be estimated. Thosevalues were estimated manually from the Percentage Viability vsConcentration dose response curves (FIG. 1).

11.5 Results

The IC₅₀ values for each compound were calculated from the individualexperiments performed and shown in FIGS. 1 and 2.

The compound toxicity to cells in culture was taken into account ininhibition experiments and in separate experiments involving increasedconcentrations of compound.

The Antiviral Index (AI) value was calculated using the formula:

${AI} = \frac{{TC}_{50}}{{IC}_{50}}$

TABLE 1 IC₅₀, TC₅₀ and AI values for test compounds against HIV-1_(Ba-L)in primary macrophages. IC₅₀ TC₅₀ Compound No. (μM) (μM) AI(3-benzoyl)cinnamoylguanidine 0.9 25-495 28-5502,3-methylenedioxycinnamoyl guanidine 1.1 >100 >915-methyl-2-napthoylguanidine 1.56 >300 >1923(indan-4-yl)-propenoylguanidine >10 >100 >105-bromo-6-methoxy-2-napthoylguanidine 0.3 >300 >10005-thiophen-3-yl-2-naphthoylguanidine 1.0 >200 >1005-(1-methylpyrazol-4-yl)2-naphthoylguanidine 2.5 >200 >80

All IC₅₀ values were estimated from the dose response curves shown inFIG. 1. TC₅₀ values were estimated in separate experiments (not shown)where concentrations of compound were greater.

Additional compounds were tested using the same assay system and doseresponse curves as described above, and their IC₅₀ was estimated. Table2 shows a summary of the data obtained.

TABLE 2 Estimated IC₅₀ values for additional compounds of the inventionTC₅₀ Compound No. IC₅₀ (μM) (μM) (1-methoxy-2-napthoyl)guanidine<2.5 >50 (3-methoxy-2-napthoyl)guanidine <2.5 >50(5-bromo-2-napthoyl)guanidine <2.5 10-50(1,4-dimethoxy--2-napthoyl)guanidine <10 10-50(6-(3-thienyl)-2-napthoyl)guanidine <0.63 <10(6-methyl-2-napthoyl)guanidine <10 10-50 (5-phenyl-2-napthoyl)guanidine<0.63 10-50 (5-(thien-2-yl)-2-napthoyl)guanidine <0.63 10-50(5-(1,3,5-trimethylpyrazol-4-yl)-2-napthoyl)guanidine >10 >50(5-(1-isobutyl-1H-pyrazol-4-yl)-2-napthoyl)guanidine <2.5 10-50(5-(3-furyl)-2-napthoyl)guanidine <0.63 10-50(5-cyclopropyl-2-napthoyl)guanidine <0.63 10-50(5-chloro-2-napthoyl)guanidine <2.5 10-50

Example 12 Anti-Viral Activity of Compounds Using the Bacterial BioassayMethod

The bacterial bioassay method used in the present example to test theanti-viral activity of the compounds against different viral targets wasdescribed in detail in PCT/2004/000866, incorporated in its entiretyherein by reference. The results of the bacterial bioassay tests aresummarised in Table 3 below. Vpu, p7 and M referred to in the table aresmall membrane proteins encoded by HIV, HCV and Dengue viruses,respectively, which have functional activities supporting viral growthand/or replication.

Although the invention has been described with reference to specificembodiments it will be understood that variations and modifications inkeeping with the principles and spirit of the invention described arealso encompassed.

TABLE 2 Mean Bacterial Bioassay Assay Scores For Compounds Of TheInvention Average Bacterial Assay Score HCV Den Compound Name BIT# Vpup7 M (3-benzoyl)cinnamoylguanidine 216 1.3 1.3 1.52,3-methylenedioxycinnamoyl guanidine 217 1.8 1.05-methyl-2-napthoylguanidine 218 1.8 1.7 1.33(indan-4-yl)-propenoylguanidine 222 1.2 2.0 2.25-bromo-6-methoxy-2-napthoylguanidine 223 0 0.05-thiophen-3-yl-2-naphthoylguanidine 224 2.2 1.1 1.35-(1-methylpyrazol-4-yl)2- 225 1.4 1.2 0.9 naphthoylguanidine3,4-dichlorocinnamoyl guanidine 300 1.52 0.67 3.40(1-methoxy-2-napthoyl)guanidine 301 1.54 0.25 0.50(3-methoxy-2-napthoyl)guanidine 302 1.04 0.42 0.50(5-bromo-2-napthoyl)guanidine 303 0.22 0.00 2.10(1,4-dimethoxy--2-napthoyl)guanidine 304 0.62 0.33 1.90(6-(3-thienyl)-2-napthoyl)guanidine 305 0.38 0.00 1.15(6-methyl-2-napthoyl)guanidine 306 0.52 0.25 2.53(5-phenyl-2-napthoyl)guanidine 307 0.12 0.08 2.40(5-(thien-2-yl)-2-napthoyl)guanidine 308 0.45 0.08 2.40(5-(1,3,5-trimethylpyrazol-4-yl)-2- 309 0.12 0.00 0.00napthoyl)guanidine (5-(1-isobutyl-1H-pyrazol-4-yl)-2- 310 0.00 0.00 1.60napthoyl)guanidine (5-(3-furyl)-2-napthoyl)guanidine 311 0.42 0.42 1.60(5-cyclopropyl-2-napthoyl)guanidine 312 0.50 0.80 2.25(5-chloro-2-napthoyl)guanidine 313 0.30 1.30 3.00(6-(1-methylpryazol-4-yl)-2- 314 0.00 3.30 1.60 napthoyl)guanidiniumacetate (5-(2,6-dimethoxypryridin-3-yl)-2- 315 0.20 0.30 1.00napthoyl)guanidine (5-(2-chlorophenyl)-2-napthoyl)guanidine 316 0.200.80 0.50 (5-(4-(acetylamino)phenyl)-2- 317 0.00 0.20 0.40napthoyl)guanidine (5-(3-(acetylamino)phenyl)-2- 318 2.00 0.30 0.35napthoyl)guanidine (5-(4-((methylsulphonyl)amino)phenyl)-2- 319 0.000.00 0.15 napthoyl)guanidine ASSAY POSITIVE CONTROL(3-Bromocinnamoyl)guanidine BIT067 2.885-bromo-2-fluorocinnamoylguanidine BIT124 2.255-(2′-bromophenyl)penta-2,4- BIT128 2.87 dienoylguanidine

REFERENCES

-   VanCott T C, Mascola J R, Loomis-Price L D, Sinangil F, Zitomersky    N, McNeil J, Robb M L, Birx D L, Barnett S. (1999) J. Virol.    73(6):4640-50-   Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P,    Desmyter J and De Clercq E. (1988) J. Virolog. Methods. 20:309-321-   D'Cruz O J, Shih M-J, Yiv S H, Chen C-L, Uckun F M. (1999) Mol. Hum.    Reprod. 5(5):421-432-   Joo, Hong-Gu. (2003) J. Vet. Sci. 4(3):229-234

The invention claimed is:
 1. A compound of Formula I: wherein

R₁ is selected from:

n is 1, 2, 3 or 4;

F is

Q is independently cycloalkyl, thienyl, furyl, pyrazolyl, substitutedpyrazolyl pyridyl, substituted pyridyl, phenyl, substituted phenyl, orheterocycle, or Q is independently

wherein R2 is straight or branched chain alkyl,

wherein R3 is

and X is hydrogen, or a pharmaceutically acceptable salt thereof.
 2. Thecompound according to claim 1, wherein the compound is selected from thegroup consisting of: (3-benzoyl)cinnamoylguanidine,3(indan-4-yl)-propenoylguanidine, 5-thiophen-3-yl-2-naphthoylguanidine,(6-(3-thienyl)-2-naphthoyl)guanidine, (5-phenyl-2-naphthoyl)guanidine,(5-(thien-2-yl)-2-naphthoyl)guanidine,(5-(1,3,5-trimethylpyrazol-4-yl)-2-naphthoyl)guanidine,(5-(1-isobutyl-1H-pyrazol-4-yl)-2-naphthoyl)guanidine,(5-(3-furyl)-2-naphthoyl)guanidine,(5-cyclopropyl-2-naphthoyl)guanidine,(5-(2,6-dimethoxypyrridin-3-yl)-2-naphthoyl)guanidine,(5-(2-chlorophenyl)-2-naphthoyl)guanidine,(5-(4-(acetylamino)phenyl)-2-naphthoyl)guanidine,(5-(3-(acetylamino)phenyl)-2-naphthoyl)guanidine,(5-(4-((methylsulphonyl)amino)phenyl)-2-naphthoyl)guanidine, andpharmaceutically acceptable salts thereof.
 3. The compound according toclaim 1 wherein the amine or imine groups of the guanidyl portion of thecompounds of Formula I can be present as the free base, a hydrate, anorganic or inorganic salt or combinations thereof.
 4. The compoundaccording to claim 1, wherein the compound has anti-viral activity. 5.The compound according to claim 1, wherein the compound is capable ofreducing, retarding or otherwise inhibiting viral growth and/orreplication.
 6. The compound according to claim 1, wherein the antiviralactivity is directed against viruses of the Flavivirus or Lentivirusfamilies.
 7. The compound according to claim 6, wherein the virus isselected from the group consisting of Hepatitis C virus (HCV), HumanImmunodeficiency Virus (HIV), and Dengue virus.
 8. The compoundaccording to claim 7, wherein the virus is selected from the groupconsisting of HCV, HIV-1, HIV-2 and Dengue virus.
 9. A pharmaceuticalcomposition comprising a compound according to claim 1, optionally incombination with one or more pharmaceutical acceptable carriers oradjuvants.
 10. The pharmaceutical composition according to claim 9,further comprising one or more known antiviral agents.
 11. A method forreducing, retarding or otherwise inhibiting growth and/or replication ofa virus comprising contacting a cell infected with said virus or exposedto said virus with a compound according to claim 1, wherein the virus isselected from the Lentivirus and Flavivirus families.
 12. A method forthe therapeutic or prophylactic treatment of a subject exposed to orinfected by a virus comprising the administration to said subject of acompound according to claim 1, wherein the virus is selected from theLentivirus and Flavivirus families.
 13. A method for the therapeutic orprophylactic treatment of a subject exposed to or infected by a viruscomprising the administration to said subject of a compound according toclaim 1 in conjunction with another one or more know antiviral agents,wherein the virus is selected from the Lentivirus and Flavivirusfamilies.
 14. The method according to claim 12, wherein the virus isselected from the group consisting of Hepatitis C virus (HCV), HumanImmunodeficiency Virus (HIV), and Dengue virus.
 15. The method accordingto claim 14, wherein the virus is selected from the group consisting ofHCV, HIV-1, HIV-2 and Dengue virus.
 16. The method according to claim12, wherein the subject undergoing therapeutic or prophylactic treatmentis a mammal selected from the group consisting of human, primate,livestock animal, companion animal, laboratory test animal or captivewild animal.